About Neurex Corporation
Neurex Corporation is a Healthcare company based in Menlo Park (United States) founded in 1994, and was acquired by Elan in April 1998. Biopharmaceutical therapies for neurological diseases and pain are developed. Its focus areas include Diversified Pharmaceuticals.
Company details
Neurex was a late-stage biopharmaceutical company developing products for neurological diseases and pain management. Its strategy was to discover, develop and commercialize its products for acute care treatment in hospital settings, such as emergency rooms, intensive care units and pain clinics. It had Corlopam approved in the US for the treatment of severe hypertension in the hospital setting. It also had non-opiate pain therapeutic Ziconotide (SNX-111) for the treatment of chronic and acute pain. It was acquired by Elan in April 2008 for 700M.
- Headquarters Menlo Park, United States
- Stage Acquired
- SectorsHealthcare
- Website neurex.com
- Acquired by Elan (Apr 1998)
Investors in Neurex Corporation
Neurex Corporation has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Elan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of OTC products, prescription pharmaceuticals, nutritional products, and APIs | 1969 | elan.com | Dublin, Ireland |
Investor details for Neurex Corporation
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Neurex Corporation
2 dated milestones of Neurex Corporation across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Neurex Corporation is founded.
- Exit Acquired by Elan.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Neurex Corporation (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neurex Corporation
Neurex Corporation was founded in 1994.
Neurex Corporation is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Neurex was a late-stage biopharmaceutical company developing products for neurological diseases and pain management. Its strategy was to discover, develop and commercialize its products for acute care treatment in hospital settings, such as emergency rooms, intensive care units and pain clinics. It had Corlopam approved in the US for the treatment of severe hypertension in the hospital setting. It also had non-opiate pain therapeutic Ziconotide (SNX-111) for the treatment of chronic and acute pain. It was acquired by Elan in April 2008 for 700M.
Neurex Corporation has 1 investor. Key investors include Elan.
Yes. Neurex Corporation was acquired by Elan in April 1998.